Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 20 Source: CRO
- €1.2 billion turnover
-
€64.5 million
profit - 773 employees
-
31st Dec 19 Source: CRO
- €1.3 billion turnover
-
€95.4 million
profit - 714 employees
- 13 more years available »
Ranking
By Turnover
(€1.2 billion)- 79th in Top Companies
- 13th in Pharma
By Employees
(773)- 267th in Top Companies
- 20th in Pharma
-
- 773
- €1.2 billion
Employees
- Johannes Schweppenhäuser Country Manager
Latest News
- May 21 Consumer giant Procter & Gamble sells last Irish manufacturing plant
- May 21 Nama clashes with Fingal council over lands with space for up to 7,000 new homes
- May 20 Attempt by investors to appoint inspector to firm ‘without precedent’, court hears
- May 20 Amarenco and SSE among groups to win green Eirgrid contracts
- May 20 Cerberus collected €113m last year from Irish loans it bought after the 2008 crash